Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccu

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation May 2022 Exhibit 99.1

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel six-month treatment for serious eye diseases, including wet age-related macular degeneration; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the success of current and future license agreements; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of our commercialized products; market acceptance of products; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. Forward Looking Statements

Compelling Pipeline Leverages Proven Durasert Technology Compelling pipeline focused on retinal disease

EYP-1901 - vorolanib (TKI) in bioerodible Durasert

Positive safety and efficacy data from Phase 1 DAVIO clinical trial

Phase 2 trial in wet AMD to begin in Q3 2022 with top line data anticipated in 2H 2023

Phase 2 trial in diabetic retinopathy to begin in 2H 2022, diabetic macular edema in 1Q 2023

Additional molecules and MOAs under evaluation

Durasert - proven intravitreal (IVT) drug delivery

Sustained local drug delivery with a single in-office IVT injection

Constant (zero-order kinetics), stable release of drug over months or years

Safely administered to thousands of patients' eyes across four FDA approved products

Strong Balance Sheet

$191 million in cash and investments on March 31, 2022

Cash runway into 2H of 2024 under current plan

Commercial franchise, YUTIQ and DEXYCU, positioned for 2022 break-even 3 | EYEPOINT PHARMACEUTICALS

5 | EYEPOINT PHARMACEUTICALS DURASERT Proven Sustained Release Intravitreal Drug Delivery PLATFORM TECHNOLOGY 4 | EYEPOINT PHARMACEUTICALS

DURASERT Safe Sustained Intravitreal Delivery Delivered by a single in-office intravitreal injection

Continuous, stable release can provide consistent and reliable drug delivery over weeks, months, or years Non-Erodible - Approved Products

YUTIQ (2018, EyePoint) - Posterior Segment Uveitis

ILUVIEN (2014, Alimera) - DME

RETISERT (2005, B&L) - Uveitis

VITRASERT (1996, B&L) - CMV retinitis Bioerodible - EYP-1901

Non-erodible polyimide coating eliminated

Drug release dynamics

Initial burst from insert surface

Constant, zero-order kinetic release rate over months

5 | EYEPOINT PHARMACEUTICALS

EYP-1901 - Vorolanib in Bioerodible Durasert Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema PIPELINE 6 | EYEPOINT PHARMACEUTICALS

EYP-1901 RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD 7 | EYEPOINT PHARMACEUTICALS Unmet Need - Real World Reality - Even One Missed Injection Can Mean Loss of Vision Study evaluated 1,041 pts getting intravitreal anti-VEGF therapies

60% went to scheduled follow up - 40% did not

Conclusion: With frequent injections required for current standard of care, a delay in care of only 5.34 weeks resulted in visual loss

Sustained release options may give practitioners and patients improved outcomes

Single injection of up to 3 inserts

Bioerodible formulation of Durasert

Initial drug burst from surface of insert potentially beneficial

Zero order kinetics release

EYP-1901 -Vorolanib in Bioerodible Durasert

A novel approach to wet AMD therapy 8 | EYEPOINT PHARMACEUTICALS Vorolanib

Receptor-binding TKI

Activity against all isoforms of VEGF and PDGF

Oral vorolanib previously studied in wet AMD phase 1 and phase 2 programs1,2 Jackson et al. JAMA Ophthalmol 2017

Cohen MN et al. Br J Ophthalmol. 2021

23 | EYEPOINT PHARMACEUTICALS Vorolanib Blocks all Isoforms of VEGF and PDGF PIPELINE

EYP-1901 VEGF-B VEGF-C VEGF-D VEGF-A R1 / INFLAMMATION R2 / BLOOD VESSEL LEAKAGE R3 / BLOOD VESSEL GROWTH & LEAKAGE VEGF SIGNALING PATHWAYS VOROLANIB 9 | EYEPOINT PHARMACEUTICALS Approved

Anti-VEGF-A therapies VOROLANIB VOROLANIB

EYP-1901 DAVIO Phase I Clinical Trial Results 10 | EYEPOINT PHARMACEUTICALS

Proof of Concept for Intravitreal Vorolanib in Wet AMD Positive Safety Data

No ocular SAEs reported

No drug-related systemic SAEs reported

Ocular AEs - majority mild and to be expected EFFICACY

and DURABILITY Positive Efficacy Data

Median time to supplemental anti-VEGF: 6 months

76 % supplemental treatment free up to 4 months

53 % supplemental treatment free up to 6 months

41 % supplemental treatment free up to 9 months

Clinically significant reduction in treatment burden by 79 % at 6 months - 75 % at 8 months SAFETY EYP-1901 DAVIO Phase 1 Clinical Trial Met all Objectives 11 | EYEPOINT PHARMACEUTICALS

BCVA: best corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: central subfield thickness EYP-1901 DAVIO Phase 1 Clinical Trial Participants

More serious disease with above average anti-VEGF injection frequency prior to enrollment 12 | EYEPOINT PHARMACEUTICALS

Ocular adverse events (AEs) specific interest:

No vitreous floaters

No retinal detachment

No implant migration in the anterior chamber

No retinal vasculitis

No posterior segment inflammation

No ocular serious adverse events (SAEs) reported

No drug-related systemic SAEs reported Ocular AEs Observed:

One eye: mild asymptomatic anterior chamber cell/flare; Treated with Maxitrol eyedrops - resolved in 8 days -no sequelae or recurrence

One eye: asymptomatic vitreous hemorrhage from injection; Observed EYP-1901 DAVIO Phase 1 Clinical Trial

Primary endpoint met with positive overall safety data at 6 months and continuing to date through 8 months 13 | EYEPOINT PHARMACEUTICALS

EYP-1901 DAVIO Phase 1 Clinical Trial Efficacy Results

Visual acuity (VA) and central subfield thickness (CST) stable 8 months after single treatment BCVA: best corrected visual acuity Interim data - monitored through 6 months For all 17 eyes at 8 months

VA = -3.0 letters OCT: optical coherence tomography; CST: central subfield thickness For all 17 eyes at 8 months

CST on OCT = + 2.4 microns 14 | EYEPOINT PHARMACEUTICALS

Interim data - monitored through 6 months EYP-1901 DAVIO Phase 1 Clinical Trial

53% and 41% of patients at 6 months and 8 months, respectively, did not require supplemental anti-VEGF treatment Median Time to supplemental anti-VEGF = 6 Months 15 | EYEPOINT PHARMACEUTICALS

SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP1901 Anti-VEGF No supplemental injection given Missed visit months 16 | EYEPOINT PHARMACEUTICALS EYP-1901 DAVIO Phase 1 Trial Clinically significant reduction in treatment burden - 79 % at six-months Interim data - monitored through 4 months

SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection given Missed visit months EYP-1901 DAVIO Phase I Trial Clinically significant reduction in treatment burden - 75 % at eight-months Interim data - monitored through 6 months 17 | EYEPOINT PHARMACEUTICALS

Screening Visit: 6 anti-VEGF injections prior to enrollment Initial Diagnosis: 9 months prior to enrollment Initial diagnosis 9 mo before enrollment Screening visit prior to treatment EYP-1901 DAVIO Phase 1 Trial Case Study

Retinal anatomy and vision maintained at 12 months following a single injection of EYP-1901 - Low dose cohort (440 g)

Month 5 - no tx EYP-1901 DAVIO Phase 1 Trial Case Study

Retinal anatomy and vision maintained at 12 months following single injection of EYP-1901 - Low dose cohort (EYP-1901 440 g)

Med Dose Case #3 Month 8 EYP-1901 DAVIO Phase 1 Trial

Eight-months after a single EYP-1901 injection, seven patients (41%) did not receive supplemental anti-VEGF treatment - anatomy and vision stable Med Dose Case #4 Month 8 Low-Mid Dose Month 8 Low Dose Month 8 Med Dose Case #1 Month 8 High Dose Month 8 Med Dose Case #2 Month 9* *Month 8 = missed visit 20 | EYEPOINT PHARMACEUTICALS

EYP-1901 DAVIO Phase 1 Trial Retrospective sub-group (n=11) analysis based on entry criteria and anticipated dosing in Phase 2 wet AMD study - 89 % reduction in treatment burden SoC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection given Missed visit months Subgroup Analysis of DAVIO Medium & High Dose Patients - Using anticipated Ph2 OCT Entry Criteria SOC Anti-VEGF Injections Before and After Treatment Reduction in Treatment Burden of 89 % overall at 8 mos Interim data - monitored through 6 months 21 | EYEPOINT PHARMACEUTICALS

EYP-1901 - Potential as a "Treat to Maintain" Therapy in wet AMD 22 | EYEPOINT PHARMACEUTICALS 1 2 Induction Treatment

Start with any standard of care (SoC) VEGF ligand inhibitor

Provides known initial visual and anatomical gains

Monthly until dry or until no further improvement - then add EYP-1901 as maintenance regimen - "treat to maintain"

Maintain with EYP-1901

May result in a less intensive treatment regimen in a majority of wet AMD eyes

May keep the majority of eyes visually and anatomically stable for six months or longer

Supplement some eyes with a VEGF ligand inhibitor as needed Sustained release of vorolanib (TKI) may maintain initial visual acuity and anatomic gains through continuous pan VEGF suppression at the receptor level

Proof of Concept for Intravitreal Vorolanib in Wet AMD Positive Safety Data

No ocular SAEs reported

No drug-related systemic SAEs reported

Ocular AEs - majority mild and to be expected EFFICACY

and DURABILITY Positive Efficacy Data

Median time to supplemental anti-VEGF: 6 months

76 % supplemental treatment free up to 4 months